Acquired C1 inhibitor deficiency
RecruitingStudy to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema
Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema
- Disease:Acquired C1 inhibitor deficiency
- Substances:Deucrictibant
Germany- Participants:18–64 years · 65+ years
- Substances:Deucrictibant
- Sponsor:Pharvaris Netherlands B.V.










